Biocon’s Vishakhapatnam API facility completes US FDA inspection

Biocon has announced that it successfully cleared the US Food and Drug Administration (FDA) audit for its active pharmaceutical ingredients (API) manufacturing facility in Vishakhapatnam, Andhra Pradesh. The audit was from September 11 to 15, 2017.
 
The facility has completed the audit without any observations. No form 483 was issued. The successful audit of this facility reflects our strong commitment to cGMP compliance at our manufacturing facilities, stated the company spokesperson.